Have a feature idea you'd love to see implemented?
Let us know!
PYXS Pyxis Oncology Inc
Price (delayed)
$2.1
Market cap
$124.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.03
Enterprise value
$131.89M
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype
Highlights
PYXS's EPS has surged by 60% year-on-year and by 17% since the previous quarter
Pyxis Oncology's net income has increased by 39% YoY and by 3.1% QoQ
PYXS's quick ratio has surged by 52% year-on-year but it is down by 23% since the previous quarter
The equity has grown by 11% YoY but it has contracted by 9% from the previous quarter
Key stats
What are the main financial stats of PYXS
Market
Valuations
Earnings
Shares outstanding
59.47M
Market cap
$124.88M
Enterprise value
$131.89M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.81
Price to sales (P/S)
7.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.17
Revenue
$16.15M
EBIT
-$57.36M
EBITDA
-$53.53M
Free cash flow
-$53.87M
Per share
Balance sheet
Liquidity
EPS
-$1.03
Free cash flow per share
-$0.89
Book value per share
$2.61
Revenue per share
$0.27
TBVPS
$2.83
Total assets
$195.31M
Total liabilities
$41.63M
Debt
$20.54M
Equity
$153.68M
Working capital
$128.55M
Debt to equity
0.13
Current ratio
7.33
Quick ratio
7.2
Net debt/EBITDA
-0.13
Margins
Efficiency
Dividend
EBITDA margin
-331.6%
Gross margin
97.1%
Net margin
-355.2%
Operating margin
-415.9%
Return on assets
-28.8%
Return on equity
-36.2%
Return on invested capital
-36.5%
Return on capital employed
-32.8%
Return on sales
-355.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PYXS stock price
How has the Pyxis Oncology stock price performed over time
Intraday
-45.03%
1 week
-50.93%
1 month
-42.93%
1 year
46.85%
YTD
16.67%
QTD
-42.78%
Financial performance
How have Pyxis Oncology's revenue and profit performed over time
Revenue
$16.15M
Gross profit
$15.67M
Operating income
-$67.16M
Net income
-$57.36M
Gross margin
97.1%
Net margin
-355.2%
Pyxis Oncology's net income has increased by 39% YoY and by 3.1% QoQ
The operating income has increased by 34% YoY and by 2.3% from the previous quarter
Pyxis Oncology's net margin has increased by 3.1% QoQ
PYXS's operating margin is up by 2.3% since the previous quarter
Growth
What is Pyxis Oncology's growth rate over time
Valuation
What is Pyxis Oncology stock price valuation
P/E
N/A
P/B
0.81
P/S
7.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.17
PYXS's EPS has surged by 60% year-on-year and by 17% since the previous quarter
PYXS's P/B is 26% below its last 4 quarters average of 1.1
The equity has grown by 11% YoY but it has contracted by 9% from the previous quarter
Efficiency
How efficient is Pyxis Oncology business performance
The ROIC has soared by 56% YoY and by 6% from the previous quarter
The return on equity rose by 43% year-on-year and by 5% since the previous quarter
Pyxis Oncology's ROA has increased by 42% YoY and by 4% from the previous quarter
PYXS's return on sales is up by 3.1% since the previous quarter
Dividends
What is PYXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PYXS.
Financial health
How did Pyxis Oncology financials performed over time
PYXS's quick ratio has surged by 52% year-on-year but it is down by 23% since the previous quarter
PYXS's current ratio is up by 49% year-on-year but it is down by 23% since the previous quarter
Pyxis Oncology's debt is 87% lower than its equity
The debt to equity has declined by 19% year-on-year but it rose by 8% since the previous quarter
The equity has grown by 11% YoY but it has contracted by 9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.